Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Studied

A double-blind phase 2 trial compared weekly semaglutide with placebo in NASH-related compensated cirrhosis.

Who / model

Adults had biopsy-confirmed NASH-related cirrhosis and met the study's BMI threshold.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Semaglutide did not significantly improve fibrosis or NASH resolution versus placebo. Liver and kidney function remained stable, with no decompensation or deaths.

Limits

The trial enrolled a relatively small group, and gastrointestinal adverse events were more frequent with semaglutide.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary